AIDS Research and Treatment · Published 2025-01-01 · DOI 10.1155/arat/6621097
Conclusion: The prevalence of dyslipidemia among people living with HIV on a dolutegravir-based ART was high, occurring in nearly three-quarters of the participants. Being female, insufficient physical activity, and being overweight or obese were significantly associated with dyslipidemia among people living with HIV taking dolutegravir-based ART. Therefore, to avoid the disastrous effects of dyslipidemia, serum lipid profiles should be considered and evaluated in people living with HIV on a dolutegravir-based ART.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →